A detailed history of Jane Street Group, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 711,425 shares of BCRX stock, worth $5.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
711,425
Previous 839,508 15.26%
Holding current value
$5.17 Million
Previous $5.19 Million 4.2%
% of portfolio
0.0%
Previous 0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.41 - $8.69 $821,012 - $1.11 Million
-128,083 Reduced 15.26%
711,425 $5.41 Million
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $1.14 Million - $1.88 Million
-277,170 Reduced 24.82%
839,508 $5.19 Million
Q1 2024

May 15, 2024

BUY
$4.89 - $7.65 $1.44 Million - $2.25 Million
293,738 Added 35.69%
1,116,678 $5.67 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $1.02 Million - $1.38 Million
204,334 Added 33.03%
822,940 $4.93 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $1.28 Million - $1.51 Million
190,826 Added 44.61%
618,606 $4.38 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $1.07 Million - $1.35 Million
153,255 Added 55.83%
427,780 $3.01 Million
Q1 2023

May 15, 2023

SELL
$7.94 - $11.84 $162,110 - $241,737
-20,417 Reduced 6.92%
274,525 $2.29 Million
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $2.38 Million - $3.22 Million
227,003 Added 334.13%
294,942 $3.39 Million
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $1.06 Million - $1.46 Million
-98,619 Reduced 59.21%
67,939 $856,000
Q2 2022

Aug 16, 2022

BUY
$7.89 - $17.88 $540,646 - $1.23 Million
68,523 Added 69.9%
166,558 $1.76 Million
Q1 2022

May 17, 2022

SELL
$11.56 - $19.76 $1.8 Million - $3.08 Million
-155,683 Reduced 61.36%
98,035 $1.59 Million
Q4 2021

Feb 15, 2022

BUY
$11.18 - $15.46 $335,813 - $464,372
30,037 Added 13.43%
253,718 $3.51 Million
Q3 2021

Nov 16, 2021

SELL
$14.21 - $17.65 $29,769 - $36,976
-2,095 Reduced 0.93%
223,681 $3.21 Million
Q2 2021

Aug 16, 2021

SELL
$9.5 - $17.24 $1.58 Million - $2.87 Million
-166,297 Reduced 42.41%
225,776 $3.57 Million
Q1 2021

May 18, 2021

BUY
$7.37 - $13.61 $1.2 Million - $2.21 Million
162,313 Added 70.64%
392,073 $3.99 Million
Q4 2020

Feb 17, 2021

BUY
$3.37 - $8.61 $468,874 - $1.2 Million
139,132 Added 153.52%
229,760 $1.71 Million
Q3 2020

Nov 17, 2020

BUY
$3.43 - $5.53 $157,495 - $253,921
45,917 Added 102.7%
90,628 $311,000
Q2 2020

Aug 17, 2020

SELL
$1.9 - $5.61 $5,705 - $16,846
-3,003 Reduced 6.29%
44,711 $213,000
Q1 2020

May 15, 2020

BUY
$1.6 - $4.11 $50,150 - $128,823
31,344 Added 191.47%
47,714 $95,000
Q4 2019

Feb 14, 2020

SELL
$1.59 - $3.45 $572 - $1,242
-360 Reduced 2.15%
16,370 $56,000
Q3 2019

Nov 14, 2019

SELL
$2.5 - $3.73 $3,852 - $5,747
-1,541 Reduced 8.43%
16,730 $48,000
Q2 2019

Aug 15, 2019

BUY
$2.91 - $9.15 $53,168 - $167,179
18,271 New
18,271 $69,000
Q1 2018

May 15, 2018

SELL
$4.35 - $5.82 $119,838 - $160,335
-27,549 Closed
0 $0
Q4 2017

Feb 15, 2018

BUY
$4.16 - $5.33 $114,603 - $146,836
27,549
27,549 $135,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.35B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.